Multiple Sclerosis

Diagnosis and management of primary progressive multiple sclerosis
Primary progressive multiple sclerosis (MS) is a chronic demyelinating degenerative disorder of the central nervous system.

Queen Square, London
UK
Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating
BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS).


USA
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
Forty relapsing multiple sclerosis patients with 1-15 gadolinium (Gd)-enhancing lesions on screening brain magnetic resonance imaging (MRI) and Expanded Disability Status Scale (EDSS) scores 0-6.5 were randomized to receive short-term induction therapy with mitoxantrone (three monthly 12 mg/m(2) infusions) followed by 12 months of daily glatiramer acetate (GA) therapy 20 mg/day subcutaneously for a total of 15 months (M-GA, n = 21) or daily GA 20 mg/day for 15 months (GA, n = 19).

Phoenix, AZ
USA
Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating
BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS).


USA
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis
BACKGROUND: Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS.

Berlin, Germany
Germany
The search for a balance between short and long-term treatment outcomes in multiple sclerosis
Multiple sclerosis is a lifelong, immune-mediated progressive disorder.
3100 St. Poelten

Austria
Combination therapies in multiple sclerosis
The last years have seen enormous progress in our understanding of pathophysiology of multiple sclerosis.

Bochum, Germany 44791
Germany
Switching algorithms: from one immunomodulatory agent to another
In spite of the availability of six disease-modifying treatments for multiple sclerosis, a significant minority of patients fail to respond adequately to treatment. severity, and the occurrence of neutralising antibodies.

Stony Brook, NY
USA
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guideline
Several lines of evidence link immunosuppression to inflammation in patients with multiple sclerosis (MS) and provide a rationale for the increasing use of immunosuppressive drugs in the treatment of MS.

Detroit, MI
USA
Will hematopoietic stem cell transplantation cure human autoimmune diseases?
Hematopoietic stem cell transplantation is becoming an accepted therapy for severe autoimmune diseases, and over 1000 patients have been transplanted worldwide.

Genova, Italy
Italy